{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:19:58Z","timestamp":1784575198343,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2024\/008\/RO5 + 6\/Seed-Sep23\/01"],"award-info":[{"award-number":["NUHSRO\/2024\/008\/RO5 + 6\/Seed-Sep23\/01"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019579","name":"SingHealth","doi-asserted-by":"publisher","award":["AM\/HRT025\/2023"],"award-info":[{"award-number":["AM\/HRT025\/2023"]}],"id":[{"id":"10.13039\/100019579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008126","name":"Dana-Farber\/Harvard Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Government of Singapore Ministry of Health","doi-asserted-by":"publisher","award":["NMRC\/CG\/C027\/2017_SHS"],"award-info":[{"award-number":["NMRC\/CG\/C027\/2017_SHS"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001068","name":"Dana Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011744","name":"National University Health System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ctrv.2025.103002","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T02:22:29Z","timestamp":1754446949000},"page":"103002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-5390","authenticated-orcid":false,"given":"Joseph J.","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy Yao","family":"Yi Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103002_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-asian adapted ESMO Clinical Practice guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2025.103002_b0010","unstructured":"National Comprehensive Cancer Network. Gastric Cancer (Version 2.2025). Accessed June 25, 2025, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"10.1016\/j.ctrv.2025.103002_b0015","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2025 JUN 1 2025;doi:10.1056\/NEJMoa2503701.","DOI":"10.1056\/NEJMoa2503701"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103002_b0020","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastrooesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103002_b0025","article-title":"Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study","volume":"42(3_suppl):247\u2013247","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103002_b0030","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12(1):9","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ctrv.2025.103002_b0035","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21(1):111","author":"Liu","year":"2021","journal-title":"BMC Med Res Method"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103002_b0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103002_b0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jrsm.45","article-title":"Individual patient data meta-analysis of time-to-event outcomes: one-stage versus two-stage approaches for estimating the hazard ratio under a random effects model","volume":"2","author":"Bowden","year":"2011","journal-title":"Res Synth Methods"},{"issue":"10184","key":"10.1016\/j.ctrv.2025.103002_b0050","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103002_b0055","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103002_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.152881","article-title":"High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features","volume":"216","author":"Liu","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"10294","key":"10.1016\/j.ctrv.2025.103002_b0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103002_b0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.21.01862","article-title":"Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103002_b0075","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103002_b0080","doi-asserted-by":"crossref","unstructured":"Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. Bmj. May 28 2024;385:e078876. doi:10.1136\/bmj-2023-078876.","DOI":"10.1136\/bmj-2023-078876"},{"key":"10.1016\/j.ctrv.2025.103002_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2022.04.027","article-title":"Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: a correlation meta-analysis","volume":"170","author":"Ajani","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:06:32Z","timestamp":1772791592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":17,"alternative-id":["S0305737225001240"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103002"}}